• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在绵羊过敏性哮喘模型中,雾化全氟溴烷和二氧化碳可迅速扩张狭窄气道。

Nebulized perflubron and carbon dioxide rapidly dilate constricted airways in an ovine model of allergic asthma.

作者信息

El Mays Tamer Y, Choudhury Parichita, Leigh Richard, Koumoundouros Emmanuel, Van der Velden Joanne, Shrestha Grishma, Pieron Cora A, Dennis John H, Green Francis Hy, Snibson Ken J

出版信息

Respir Res. 2014 Sep 16;15(1):98. doi: 10.1186/s12931-014-0098-x.

DOI:10.1186/s12931-014-0098-x
PMID:25355286
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4172894/
Abstract

BACKGROUND

The low toxicity of perfluorocarbons (PFCs), their high affinity for respiratory gases and their compatibility with lung surfactant have made them useful candidates for treating respiratory diseases such as adult respiratory distress syndrome. We report results for treating acute allergic and non-allergic bronchoconstriction in sheep using S-1226 (a gas mixture containing carbon dioxide and small volumes of nebulized perflubron). The carbon dioxide, which is highly soluble in perflubron, was used to relax airway smooth muscle.

METHODS

Sheep previously sensitized to house dust mite (HDM) were challenged with HDM aerosols to induce early asthmatic responses. At the maximal responses (characterised by an increase in lung resistance), the sheep were either not treated or treated with one of the following; nebulized S-1226 (perflubron + 12% CO2), nebulized perflubron + medical air, 12% CO2, salbutamol or medical air. Lung resistance was monitored for up to 20 minutes after cessation of treatment.

RESULTS

Treatment with S-1226 for 2 minutes following HDM challenge resulted in a more rapid, more profound and more prolonged decline in lung resistance compared with the other treatment interventions. Video bronchoscopy showed an immediate and complete (within 5 seconds) re-opening of MCh-constricted airways following treatment with S-1226.

CONCLUSIONS

S-1226 is a potent and rapid formulation for re-opening constricted airways. Its mechanism(s) of action are unknown. The formulation has potential as a rescue treatment for acute severe asthma.

摘要

背景

全氟化碳(PFCs)毒性低、对呼吸气体亲和力高且与肺表面活性剂具有相容性,使其成为治疗诸如成人呼吸窘迫综合征等呼吸系统疾病的理想候选物质。我们报告了使用S - 1226(一种含有二氧化碳和少量雾化全氟溴辛烷的气体混合物)治疗绵羊急性过敏性和非过敏性支气管收缩的结果。高度溶于全氟溴辛烷的二氧化碳用于舒张气道平滑肌。

方法

预先对屋尘螨(HDM)致敏的绵羊用HDM气雾剂激发以诱导早期哮喘反应。在出现最大反应(以肺阻力增加为特征)时,对绵羊不进行治疗或采用以下其中一种方法进行治疗;雾化S - 1226(全氟溴辛烷 + 12%二氧化碳)、雾化全氟溴辛烷 + 医用空气、12%二氧化碳、沙丁胺醇或医用空气。治疗停止后监测肺阻力长达20分钟。

结果

与其他治疗干预措施相比,HDM激发后用S - 1226治疗2分钟导致肺阻力下降更快、更显著且更持久。视频支气管镜检查显示,用S - 1226治疗后,MCh收缩的气道立即(5秒内)完全重新开放。

结论

S - 1226是一种强效且快速的使收缩气道重新开放的制剂。其作用机制尚不清楚。该制剂有潜力作为急性重度哮喘的抢救治疗药物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c93a/4172894/4357876b18c9/12931_2014_98_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c93a/4172894/20c7063b030d/12931_2014_98_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c93a/4172894/9a93f4011fb1/12931_2014_98_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c93a/4172894/ef8a08051198/12931_2014_98_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c93a/4172894/4357876b18c9/12931_2014_98_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c93a/4172894/20c7063b030d/12931_2014_98_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c93a/4172894/9a93f4011fb1/12931_2014_98_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c93a/4172894/ef8a08051198/12931_2014_98_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c93a/4172894/4357876b18c9/12931_2014_98_Fig4_HTML.jpg

相似文献

1
Nebulized perflubron and carbon dioxide rapidly dilate constricted airways in an ovine model of allergic asthma.在绵羊过敏性哮喘模型中,雾化全氟溴烷和二氧化碳可迅速扩张狭窄气道。
Respir Res. 2014 Sep 16;15(1):98. doi: 10.1186/s12931-014-0098-x.
2
A phase IIa proof-of-concept, placebo-controlled, randomized, double-blind, crossover, single-dose clinical trial of a new class of bronchodilator for acute asthma.一项针对新型支气管扩张剂治疗急性哮喘的IIa期概念验证、安慰剂对照、随机、双盲、交叉、单剂量临床试验。
Trials. 2018 Jun 18;19(1):321. doi: 10.1186/s13063-018-2720-6.
3
A phase I, placebo-controlled, randomized, double-blind, single ascending dose-ranging study to evaluate the safety and tolerability of a novel biophysical bronchodilator (S-1226) administered by nebulization in healthy volunteers.一项I期、安慰剂对照、随机、双盲、单剂量递增范围研究,旨在评估雾化吸入新型生物物理支气管扩张剂(S-1226)在健康志愿者中的安全性和耐受性。
Trials. 2016 Jul 28;17:361. doi: 10.1186/s13063-016-1489-8.
4
Chronic airway disease: deteriorating pulmonary function in sheep associated with repeated challenges of house dust mite.慢性气道疾病:绵羊肺功能恶化与反复接触屋尘螨有关。
Exp Lung Res. 2006 Aug;32(7):321-30. doi: 10.1080/01902140600916960.
5
Assessment of peripheral airway function following chronic allergen challenge in a sheep model of asthma.哮喘绵羊模型中慢性变应原刺激后周围气道功能的评估。
PLoS One. 2011;6(12):e28740. doi: 10.1371/journal.pone.0028740. Epub 2011 Dec 12.
6
Dietary galacto-oligosaccharides prevent airway eosinophilia and hyperresponsiveness in a murine house dust mite-induced asthma model.在小鼠屋尘螨诱导的哮喘模型中,膳食低聚半乳糖可预防气道嗜酸性粒细胞增多和高反应性。
Respir Res. 2015 Feb 7;16(1):17. doi: 10.1186/s12931-015-0171-0.
7
Dynamics of IL-4 and IL-13 expression in the airways of sheep following allergen challenge.变应原激发后绵羊气道中白细胞介素-4和白细胞介素-13表达的动态变化
BMC Pulm Med. 2015 Sep 11;15:101. doi: 10.1186/s12890-015-0097-9.
8
Antigen-induced mast cell expansion and bronchoconstriction in a mouse model of asthma.哮喘小鼠模型中抗原诱导的肥大细胞扩增和支气管收缩。
Am J Physiol Lung Cell Mol Physiol. 2014 Jan;306(2):L196-206. doi: 10.1152/ajplung.00055.2013. Epub 2013 Nov 27.
9
Increased mast cell density and airway responses to allergic and non-allergic stimuli in a sheep model of chronic asthma.在慢性哮喘绵羊模型中,肥大细胞密度增加,对变应原和非变应原刺激的气道反应增强。
PLoS One. 2012;7(5):e37161. doi: 10.1371/journal.pone.0037161. Epub 2012 May 14.
10
Effects of superimposed pressure oscillations on a chronic sensitized airways mouse model.叠加压力振荡对慢性致敏气道小鼠模型的影响。
Am J Physiol Lung Cell Mol Physiol. 2020 May 1;318(5):L900-L907. doi: 10.1152/ajplung.00348.2019. Epub 2020 Feb 26.

引用本文的文献

1
Carbon dioxide and MAPK signalling: towards therapy for inflammation.二氧化碳与 MAPK 信号转导:炎症治疗的新靶点
Cell Commun Signal. 2023 Oct 10;21(1):280. doi: 10.1186/s12964-023-01306-x.
2
Asthmatic allergen inhalation sensitises carotid bodies to lysophosphatidic acid.哮喘变应原吸入使颈动脉体对溶血磷脂酸敏感。
J Neuroinflammation. 2021 Aug 31;18(1):191. doi: 10.1186/s12974-021-02241-9.
3
Humidified Warmed CO Treatment Therapy Strategies Can Save Lives With Mitigation and Suppression of SARS-CoV-2 Infection: An Evidence Review.

本文引用的文献

1
Severe refractory asthma: an update.严重难治性哮喘:更新。
Eur Respir Rev. 2013 Sep 1;22(129):227-35. doi: 10.1183/09059180.00001913.
2
Surfactant and allergic airway inflammation.表面活性物质与过敏性气道炎症。
Swiss Med Wkly. 2013 Jul 29;143:w13818. doi: 10.4414/smw.2013.13818. eCollection 2013.
3
Pathogenesis of small airways in asthma.哮喘中小气道的发病机制。
加湿温热二氧化碳治疗策略可通过减轻和抑制SARS-CoV-2感染挽救生命:一项证据综述。
Front Med (Lausanne). 2020 Dec 11;7:594295. doi: 10.3389/fmed.2020.594295. eCollection 2020.
4
A phase IIa proof-of-concept, placebo-controlled, randomized, double-blind, crossover, single-dose clinical trial of a new class of bronchodilator for acute asthma.一项针对新型支气管扩张剂治疗急性哮喘的IIa期概念验证、安慰剂对照、随机、双盲、交叉、单剂量临床试验。
Trials. 2018 Jun 18;19(1):321. doi: 10.1186/s13063-018-2720-6.
5
A phase I, placebo-controlled, randomized, double-blind, single ascending dose-ranging study to evaluate the safety and tolerability of a novel biophysical bronchodilator (S-1226) administered by nebulization in healthy volunteers.一项I期、安慰剂对照、随机、双盲、单剂量递增范围研究,旨在评估雾化吸入新型生物物理支气管扩张剂(S-1226)在健康志愿者中的安全性和耐受性。
Trials. 2016 Jul 28;17:361. doi: 10.1186/s13063-016-1489-8.
6
Variability of the Sheep Lung Microbiota.绵羊肺部微生物群的变异性
Appl Environ Microbiol. 2016 May 16;82(11):3225-3238. doi: 10.1128/AEM.00540-16. Print 2016 Jun 1.
Respiration. 2012;84(1):4-11. doi: 10.1159/000339550. Epub 2012 Jun 29.
4
Effect of asthma exacerbations on health care costs among asthmatic patients with moderate and severe persistent asthma.中重度持续性哮喘患者哮喘恶化对医疗成本的影响。
J Allergy Clin Immunol. 2012 May;129(5):1229-35. doi: 10.1016/j.jaci.2012.01.039. Epub 2012 Feb 11.
5
Carbon dioxide enhances substance P-induced epithelium-dependent bronchial smooth muscle relaxation in Sprague-Dawley rats.二氧化碳增强了 P 物质诱导的 Sprague-Dawley 大鼠上皮依赖性支气管平滑肌松弛。
Can J Physiol Pharmacol. 2011 Jul;89(7):513-20. doi: 10.1139/y11-052.
6
Management of severe acute asthma in the emergency department.急诊科严重急性哮喘的管理。
Curr Opin Crit Care. 2011 Aug;17(4):335-41. doi: 10.1097/MCC.0b013e328348bf09.
7
Airway disease: the use of large animal models for drug discovery.气道疾病:药物发现中大型动物模型的应用。
Pulm Pharmacol Ther. 2011 Oct;24(5):525-32. doi: 10.1016/j.pupt.2011.02.001. Epub 2011 Feb 26.
8
Canadian Thoracic Society Asthma Management Continuum--2010 Consensus Summary for children six years of age and over, and adults.加拿大胸科协会哮喘管理连续性--2010 年共识总结,适用于 6 岁及以上儿童和成人。
Can Respir J. 2010 Jan-Feb;17(1):15-24. doi: 10.1155/2010/827281.
9
The FDA and safe use of long-acting beta-agonists in the treatment of asthma.美国食品药品监督管理局与长效β受体激动剂在哮喘治疗中的安全使用。
N Engl J Med. 2010 Apr 1;362(13):1169-71. doi: 10.1056/NEJMp1002074. Epub 2010 Feb 24.
10
Effects of budesonide and formoterol on allergen-induced airway responses, inflammation, and airway remodeling in asthma.布地奈德和福莫特罗对哮喘变应原诱导的气道反应、炎症和气道重塑的影响。
J Allergy Clin Immunol. 2010 Feb;125(2):349-356.e13. doi: 10.1016/j.jaci.2009.09.011. Epub 2009 Dec 6.